Prospects for gene therapy of haemophilia

被引:40
作者
Nathwani, AC
Davidoff, AM
Tuddenham, EGD
机构
[1] UCL, Dept Haematol, London WC1E 6HX, England
[2] St Jude Childrens Res Hosp, Dept Surg, Memphis, TN 38105 USA
[3] Hammersmith Hosp, Imperial Coll, MRC Thrombosis & Haemostasis Res, London, England
关键词
gene therapy; haemophilia; insertional mutagenesis;
D O I
10.1111/j.1365-2516.2004.00926.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
That gene therapy offers the promise of a cure for haemophilia was apparent more than a decade ago. After years of failure, substantial progress in the efficiency of gene transfer technology has recently resulted in impressive success in animal models with haemophilia. However, fears of the risks intrinsic to such therapy have been raised by the fate of two children cured of immune deficiency by gene transfer who have, however, subsequently developed leukaemia as a result of insertional mutagenesis. The purpose of this review is to outline the current status of gene therapy in light of recent successes and tragedies and to consider the prospects for curing haemophilia in the short-to-medium term.
引用
收藏
页码:309 / 318
页数:10
相关论文
共 50 条
[1]   Sustained high-level expression of full-length human factor VIII and restoration of clotting activity in hemophilic mice using a minimal adenovirus vector [J].
Balagué, C ;
Zhou, JM ;
Dai, YF ;
Alemany, R ;
Josephs, SF ;
Andreason, G ;
Hariharan, M ;
Sethi, E ;
Prokopenko, E ;
Jan, HY ;
Lou, YC ;
Hubert-Leslie, D ;
Ruiz, L ;
Zhang, WW .
BLOOD, 2000, 95 (03) :820-828
[2]   Helper-dependent adenoviral vectors mediate therapeutic factor VIII expression for several months with minimal accompanying toxicity in a canine model of severe hemophilia A [J].
Brown, BD ;
Shi, CX ;
Powell, S ;
Hurlbut, D ;
Graham, FL ;
Lillicrap, D .
BLOOD, 2004, 103 (03) :804-810
[3]   Coexpression of factor VIII heavy and light chain adeno-associated viral vectors produces biologically active protein [J].
Burton, M ;
Nakai, H ;
Colosi, P ;
Cunningham, J ;
Mitchell, R ;
Couto, L .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (22) :12725-12730
[4]   Phenotype correction of hemophilia A mice by spliceosome-mediated RNA trans-splicing [J].
Chao, HJ ;
Mansfield, SG ;
Bartel, RC ;
Hiriyanna, S ;
Mitchell, LG ;
Garcia-Blanco, M ;
Walsh, CE .
NATURE MEDICINE, 2003, 9 (08) :1015-1019
[5]   Sustained expression of human factor VIII in mice using a parvovirus-based vector [J].
Chao, HJ ;
Nao, L ;
Bruce, AT ;
Walsh, CE .
BLOOD, 2000, 95 (05) :1594-1599
[6]   Linear DNAs concatemerize in vivo and result in sustained transgene expression in mouse liver [J].
Chen, ZY ;
Yant, SR ;
He, CY ;
Meuse, L ;
Shen, S ;
Kay, MA .
MOLECULAR THERAPY, 2001, 3 (03) :403-410
[7]   Immune responses to adenovirus and adeno-associated virus in humans [J].
Chirmule, N ;
Propert, KJ ;
Magosin, SA ;
Qian, Y ;
Qian, R ;
Wilson, JM .
GENE THERAPY, 1999, 6 (09) :1574-1583
[8]   Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors [J].
Chuah, MKL ;
Schiedner, G ;
Thorrez, L ;
Brown, B ;
Johnston, M ;
Gillijns, V ;
Hertel, S ;
Van Rooijen, N ;
Lillicrap, D ;
Collen, D ;
VandenDriessche, T ;
Kochanek, S .
BLOOD, 2003, 101 (05) :1734-1743
[9]   Complete short-term correction of canine hemophilia A by in vivo gene therapy [J].
Connelly, S ;
Mount, J ;
Mauser, A ;
Gardner, JM ;
Kaleko, M ;
McClelland, A ;
Lothrop, CD .
BLOOD, 1996, 88 (10) :3846-3853
[10]   Gene therapy insertional mutagenesis insights [J].
Davé, UP ;
Jenkins, NA ;
Copeland, NG .
SCIENCE, 2004, 303 (5656) :333-333